The architecture behind real-world oncology decisions.
We build research-grade clinical decision support for oncology. Our proprietary architecture helps pharma and diagnostics companies close the gap between approval and real-world uptake. We support the decisions that guidelines don't resolve.
Built to close the gap between
approval and real-world use
Drug approval doesn't guarantee uptake. Eligible patients don't always get treated. We build the tools that help physicians navigate the decisions that fall between what guidelines say and what a patient actually needs.
CDS Pipeline Architecture
A proprietary research-grade architecture for building clinical decision support at scale. Modular, evidence-linked, and designed to be built around specific oncology assets rather than generic guidelines.
Asset-Specific Decision Support
CDS tools built around your drug or diagnostic. We work with pharma and diagnostics companies to design decision support that increases appropriate use in the patients most likely to benefit.
Strategic Advisory
Guidance on CDS strategy, real-world uptake, and market access from a physician who has worked end-to-end: from early drug development through launch, HTA submissions, and health system adoption.
Precision Path:
What our architecture can build
We built Precision Path on our own architecture to demonstrate what research-grade oncology CDS actually looks like. It's a multi-tumor decision support system covering Breast Cancer, GIST, and Kidney Cancer. It exists to show partners what we can build for their specific asset.
- Scalable core engine, extensible to any tumor type
- 160+ personalized pathway steps across 3 tumor types
- Genomic and clinical inputs synthesized into treatment guidance
- Built to be adapted for asset-specific partner deployments
Built by someone who has seen
every stage of the drug lifecycle
Dr. Henry Conter is a practicing medical oncologist at William Osler Health System and founder of Kesis & Sisters. He has worked end-to-end: from early drug development decisions at Hoffmann-La Roche (including recommending the termination of a pre-clinical asset), through global launch strategy, real-world in-market execution, Canadian Drug Agency HTA submissions, and health system leadership. He built Kesis & Sisters because he understood, from both sides, why approved drugs don't reach the patients who need them.
Full Story & CredentialsWondering what CDS could do
for your asset?
If you're a pharma or diagnostics company thinking about the gap between where your drug or test is approved and where it's actually being used, that's the conversation we're built for.
Stay in the loop
New thinking on oncology decision-making, health technology, and clinical strategy. No schedule, no noise — just when there's something worth sharing.